[
    [
        {
            "time": "",
            "original_text": "益方生物忙着上市似乎有点早：无产品、无盈利 研发成果尚存不确定性、募投项目用地也未落实",
            "features": {
                "keywords": [
                    "益方生物",
                    "上市",
                    "无产品",
                    "无盈利",
                    "研发成果",
                    "不确定性",
                    "募投项目",
                    "用地未落实"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "益方生物忙着上市似乎有点早：无产品、无盈利 研发成果尚存不确定性、募投项目用地也未落实",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "聚焦IPO | 无产品、无盈利，研发成果尚存不确定性，募投项目用地也未落实，益方生物忙着上市似乎有点早！",
            "features": {
                "keywords": [
                    "IPO",
                    "益方生物",
                    "无产品",
                    "无盈利",
                    "研发成果",
                    "不确定性",
                    "募投项目",
                    "用地未落实"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "聚焦IPO | 无产品、无盈利，研发成果尚存不确定性，募投项目用地也未落实，益方生物忙着上市似乎有点早！",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "肺癌靶向药物的“速度与激情”",
            "features": {
                "keywords": [
                    "肺癌",
                    "靶向药物",
                    "速度与激情"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "肺癌靶向药物的“速度与激情”",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 2,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "贝达药业埃克替尼新适应症申请进入「在审批」",
            "features": {
                "keywords": [
                    "贝达药业",
                    "埃克替尼",
                    "新适应症",
                    "审批"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "贝达药业埃克替尼新适应症申请进入「在审批」",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "贝达药业股份有限公司获批8亿美元在香港上市",
            "features": {
                "keywords": [
                    "贝达药业",
                    "香港上市",
                    "8亿美元"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "贝达药业股份有限公司获批8亿美元在香港上市",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 10,
                "Impact": 9,
                "Duration": 9,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 10
            }
        }
    ]
]